LISCure Biosciences
Seoul
About LISCure Biosciences
LISCure Biosciences is a developer of bacteria-mediated immunotherapy designed to treat tumors as well as degenerative neurological, autoimmune and metabolic diseases. The company currently has seven pipelines of medicine and two pipelines of health-functioning food and is considering the introduction of two more pipes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $15.7M
- Funding stage: Early Stage Venture
- Last round: Series B (Dec 2020)
- Website: liscure.bio
- Phone: 02-3443-1800
Industries & Categories
Biotechnology, Health Care
Canonical: https://fsome.com/organization/liscure-biosciences-95973 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.